Recent Updates
Recently added Catalysts
INDV Positive Sentiment

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Friday, July 25, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Indivior PLC has announced the cancellation of its secondary listing on the London Stock Exchange, effective July 25, 2025. The company will continue to maintain its primary listing on the Nasdaq Stock Market. This decision follows an earlier announcement made on June 2, 2025, and is part of Indivior's strategy to focus on its primary market.
Price reaction · baseline $16.81 (2025-07-24 close) · hit pre-market · clean, no other INDV news in the window
day 0 close · peak
+2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior maintains its primary listing on Nasdaq.
  • The cancellation of the secondary listing may streamline operations.
  • Indivior continues to focus on developing treatments for opioid use disorder.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
5.4%
average across 2 past catalysts
Lead asset
RBP-6000
Phase 3 · Opioid Use Disorder

Full Press Release Details

SLOUGH, United KingdomandRICHMOND, Va.,July 25, 2025/PRNewswire/ -- Further to the announcement made onJune 2, 2025, Indivior PLC (Nasdaq:INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effect from08:00 a.m.UK time today,July 25, 2025(the "London Delisting"). Indivior continues to maintain its primary listing of Ordinary Shares on the Nasdaq Stock Market.
Indivior has prepared an FAQ document for shareholders in connection with the London Delisting, which is available athttps://www.indivior.com/en/investors/shareholder-information.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered inthe United StatesinRichmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visitwww.indivior.comto learn more. Connect with Indivior on LinkedIn by visitingwww.linkedin.com/company/indivior.

Frequently Asked Questions

What was announced by Indivior on July 25, 2025?

Indivior announced the cancellation of its secondary listing on the London Stock Exchange.

Is Indivior still listed on the Nasdaq?

Yes, Indivior continues to maintain its primary listing on the Nasdaq Stock Market.

Why did Indivior cancel its London listing?

The cancellation is part of Indivior's strategy to focus on its primary market.

Where can shareholders find more information?

Shareholders can access an FAQ document on Indivior's website.

ShareAdd on Google
Tags: INDV Viatris Investor Conferences Healthcare Indivior Nasdaq London Stock Exchange opioid use disorder pharmaceutical company
Last updated: Jul 25, 2025

Biotech snapshot

Cash runway
$222M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RBP-6000Phase 3
Opioid Use Disorder →

Catalyst track record

+35%
best trade around INDV's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for INDV.

See every catalyst's timing & PoA →